Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors

  title={Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors},
  author={J. Tobert},
  journal={Nature Reviews Drug Discovery},
  • J. Tobert
  • Published 2003
  • Medicine
  • Nature Reviews Drug Discovery
  • In the 1950s and 1960s, it became apparent that elevated concentrations of plasma cholesterol were a major risk factor for the development of coronary heart disease, which led to the search for drugs that could reduce plasma cholesterol. One possibility was to reduce cholesterol biosynthesis, and the rate-limiting enzyme in the cholesterol biosynthetic pathway, 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase, was a natural target. Here, I describe the discovery and development of lovastatin… CONTINUE READING
    642 Citations
    Pleiotropic Effects of HMG-CoA Reductase Inhibitors - studies in vitro and in vivo
    • 1
    Novel 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors: a patent review
    • 11
    The Toxicology of HMG—CoA Reductase Inhibitors: Prediction of Human Risk
    • 35
    • Highly Influenced
    A review on lovastatin and its production
    • 25
    Mechanisms of statin-induced myopathy: a role for the ubiquitin-proteasome pathway?
    • 23
    HMG-CoA Reductase inhibitors: an updated review of patents of novel compounds and formulations (2011-2015)
    • 8
    The increasingly complex mechanism of HMG-CoA reductase.
    • 27


    Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol.
    • 252
    HMG-CoA reductase inhibitor-induced myopathy in the rat: cyclosporine A interaction and mechanism studies.
    • 147
    New lipid-modifying therapies
    • E. Bruckert
    • Medicine
    • Expert opinion on investigational drugs
    • 2003
    • 9
    Risk for myopathy with statin therapy in high-risk patients.
    • 443
    • PDF